Phathom Pharmaceuticals Ownership
| PHAT Stock | USD 6.23 0.03 0.48% |
Shares in Circulation | First Issued 2018-09-30 | Previous Quarter 65 M | Current Value 63 M | Avarage Shares Outstanding 36.6 M | Quarterly Volatility 17.7 M |
Phathom |
Phathom Stock Ownership Analysis
About 97.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 5.29. Phathom Pharmaceuticals had not issued any dividends in recent years. Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Phathom Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people. To find out more about Phathom Pharmaceuticals contact Terrie Curran at 877 742 8466 or learn more at https://www.phathompharma.com.Besides selling stocks to institutional investors, Phathom Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Phathom Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Phathom Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Phathom Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Phathom Pharmaceuticals Insider Trades History
Roughly 4.0% of Phathom Pharmaceuticals are currently held by insiders. Unlike Phathom Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Phathom Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Phathom Pharmaceuticals' insider trades
Phathom Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Phathom Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Phathom Pharmaceuticals backward and forwards among themselves. Phathom Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Phathom Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Catalys Pacific Llc | 2024-12-31 | 1.2 M | Gw&k Investment Management, Llc | 2024-12-31 | 1.1 M | State Street Corp | 2024-12-31 | 1 M | 683 Capital Management Llc | 2024-12-31 | 1 M | Geode Capital Management, Llc | 2024-12-31 | 1 M | Woodline Partners Lp | 2024-12-31 | 1 M | Propel Bio Management Llc | 2024-12-31 | 989.9 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 966.4 K | Fmr Inc | 2024-12-31 | 801.4 K | Medicxi Ventures Management (jersey) Ltd | 2024-09-30 | 7.5 M | Jennison Associates Llc | 2024-12-31 | 7.1 M |
Phathom Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Phathom Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Phathom Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Phathom Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Phathom Pharmaceuticals Outstanding Bonds
Phathom Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Phathom Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Phathom bonds can be classified according to their maturity, which is the date when Phathom Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US717265AM45 Corp BondUS717265AM45 | View | |
| FCX 7125 01 NOV 27 Corp BondUS717265AJ16 | View | |
| US717265AL61 Corp BondUS717265AL61 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Phathom Pharmaceuticals Corporate Filings
F4 | 21st of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 6th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 11th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 12th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.